# China NMPA Drug Inspection - Jiangsu Tongji Traditional Chinese Medicine Pieces Co., Ltd. - Black-striped snake

Source: https://www.globalkeysolutions.net/records/china_drug_inspection/jiangsu-tongji-traditional-chinese-medicine-pieces-co-ltd/66db2008-76e5-4a0d-931f-9c90ccb100f1/
Source feed: China

> China NMPA drug inspection for Jiangsu Tongji Traditional Chinese Medicine Pieces Co., Ltd. published April 09, 2021. Drug: Black-striped snake. On April 9, 2021, the Jiangsu Provincial Drug Administration released its first-quarter report identifying 18 batches of

---

## Details

- Record Type: CHINA_DRUG_INSPECTION
- Title: Announcement on the Quality of Drugs in Jiangsu Province, First Quarter of 2021 (No. 6 of 2021)
- Company Name: Jiangsu Tongji Traditional Chinese Medicine Pieces Co., Ltd.
- Publication Date: 2021-04-09
- Drug Name: Black-striped snake
- Inspection Finding: Non-compliant item: Appearance:; Remarks: Confirmed counterfeit.
- Action Taken: Risk control measures such as suspending sales and use will be implemented, investigations will be conducted to address the reasons for non-compliance, and rectification will be carried out in accordance with the law.
- Summary: On April 9, 2021, the Jiangsu Provincial Drug Administration released its first-quarter report identifying 18 batches of non-compliant pharmaceutical products. The inspection covered various manufacturers and suppliers, including Yuanhe Pharmaceutical Co., Ltd., Hubei Hepu Pharmaceutical Co., Ltd., and several traditional medicine processors such as Suzhou Chunhuitang and Jiangsu Tongji. The violations identified ranged from physical defects, such as improper appearance and excessive moisture, to critical quality issues like high impurity levels, poor content uniformity, and insufficient active ingredients. Notably, the report highlighted three instances of confirmed counterfeit products, including Sildenafil Citrate and specific herbal medicines. These inspections were conducted under the regulatory framework of the Chinese Pharmacopoeia (2015 Edition) and relevant national drug standards. In response to these findings, the provincial drug administration has mandated that all involved enterprises immediately suspend the sale and use of the affected batches. The companies are required to investigate the root causes of these failures and implement corrective actions. Furthermore, local regulatory departments have initiated legal investigations and administrative punishments against the non-compliant organizations to ensure industry integrity and protect public health.

Company: https://www.globalkeysolutions.net/companies/jiangsu-tongji-traditional-chinese-medicine-pieces-co-ltd/8963181f-d6aa-4f50-9863-1ef7e32176d4/